These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33804504)

  • 21. Precision medicine for Parkinson's disease: The subtyping challenge.
    Frasier M; Fiske BK; Sherer TB
    Front Aging Neurosci; 2022; 14():1064057. PubMed ID: 36533178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's Disease and the Environment.
    Ball N; Teo WP; Chandra S; Chapman J
    Front Neurol; 2019; 10():218. PubMed ID: 30941085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome.
    Postuma RB; Weintraub D; Simuni T; Rodríguez-Violante M; Leentjens AFG; Hu MT; Espay AJ; Erro R; Dujardin K; Bohnen NI; Berg D; Mestre TA; Marras C
    Mov Disord Clin Pract; 2024 Aug; 11(8):983-991. PubMed ID: 38817000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).
    Nalls MA; Keller MF; Hernandez DG; Chen L; Stone DJ; Singleton AB;
    Mov Disord; 2016 Jan; 31(1):79-85. PubMed ID: 26268663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Emerging concepts for precision medicine in Parkinson's disease with focus on genetics].
    Stute L; Krüger R
    Fortschr Neurol Psychiatr; 2020 Sep; 88(9):558-566. PubMed ID: 32485745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotection in Parkinson's disease.
    Schapira AH
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S41-3. PubMed ID: 20123556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visuomotor control in patients with Parkinson's disease.
    Chen J; Ho SL; Lee TM; Chang RS; Pang SY; Li L
    Neuropsychologia; 2016 Jan; 80():102-114. PubMed ID: 26529488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics of drug response in Parkinson's disease.
    Džoljić E; Novaković I; Krajinovic M; Grbatinić I; Kostić V
    Int J Neurosci; 2015; 125(9):635-44. PubMed ID: 25226559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological and Clinical Implications of Comorbidities in Parkinson's Disease.
    Santiago JA; Bottero V; Potashkin JA
    Front Aging Neurosci; 2017; 9():394. PubMed ID: 29255414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.
    Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM; Chen-Plotkin AS
    Mov Disord; 2015 Oct; 30(12):1648-56. PubMed ID: 26207725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of Parkinson's Disease: An Introduction.
    Titova N; Qamar MA; Chaudhuri KR
    Int Rev Neurobiol; 2017; 132():183-196. PubMed ID: 28554407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's at risk syndrome: can Parkinson's disease be predicted?
    Stern MB; Siderowf A
    Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression?
    Fereshtehnejad SM; Postuma RB
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):34. PubMed ID: 28324303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
    Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
    Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetics in parkinson's disease: From better disease understanding to machine learning based precision medicine.
    Aborageh M; Krawitz P; Fröhlich H
    Front Mol Med; 2022; 2():933383. PubMed ID: 39086979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneous Determinants of Quality of Life in Different Phenotypes of Parkinson's Disease.
    Fereshtehnejad SM; Shafieesabet M; Farhadi F; Hadizadeh H; Rahmani A; Naderi N; Khaefpanah D; Shahidi GA; Delbari A; Lökk J
    PLoS One; 2015; 10(9):e0137081. PubMed ID: 26335773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD.
    Artusi CA; Lopiano L; Morgante F
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33291579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated review of Parkinson's disease genetics and clinicopathological correlations.
    Ferreira M; Massano J
    Acta Neurol Scand; 2017 Mar; 135(3):273-284. PubMed ID: 27273099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.
    Ryden LE; Lewis SJG
    Drugs Aging; 2019 Feb; 36(2):103-113. PubMed ID: 30556112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.